Professor Philippe Moreau currently holds the position of Head of the Hematology Department at the University Hospital of Nantes, France, and was appointed University Professor of Clinical Hematology in 2003. Specializing in clinical hematology, he has led many pivotal clinical trials and is the principal investigator of numerous trials currently underway to test novel agents and different combined regimens.
Professor Moreau holds a number of additional positions: he is a member of the administration council of the Intergroupe Francophone du Myélome (IFM), he was chairman of the International Myeloma Foundation (IFM) from 2006 to 2009, and is currently a board member for the International Myeloma Society (IMS).
Professor Moreau has published an enviable number of peer-reviewed articles and is widely known for his work on the treatment of MM with high-dose therapy and novel agents. As a leading researcher in MM, he is head of the unit for early phase I and phase II trials in clinical hematology at the University Hospital of Nantes. He is a frequently invited speaker at international hematology/oncology meetings and is a highly regarded amongst his peers. He took up the role of co-Chair of the Multiple Myeloma Hub in April 2017.